New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Generate Biomedicines, Inc. (GENB) vs MannKind Corporation (MNKD)

Generate Biomedicines, Inc. and MannKind Corporation are both Biotechnology companies. Generate Biomedicines, Inc. and MannKind Corporation are of similar size ($1.4B and $1.3B). MannKind Corporation has the higher net margin (−18.1% vs −1,326.8%) and the lower return on invested capital (−2.58% vs 0.00%). Across the 15 metrics below, MannKind Corporation leads on 9 and Generate Biomedicines, Inc. on 6.

Valuation

Metric GENB MNKD Biotechnology median
P/E n/m n/m 8.26
P/S 63.31 3.05 9.20
P/B 3.50 n/m 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m 102.26 0.67
EV/Sales 44.41 3.84 9.05
Earnings yield (39.94%) (5.84%) (34.24%)
Free cash flow yield (18.94%) (6.22%) (24.77%)

Profitability

Metric GENB MNKD Biotechnology median
Gross margin 100.00% 75.76% 70.18%
Operating margin (1,382.04%) (2.88%) 0.00%
Net margin (1,326.75%) (18.10%) 0.00%
Free cash flow margin (1,199.36%) (18.97%) 0.00%
Return on equity 1,047.66% 182.90% (51.58%)
Return on assets (54.06%) (12.29%) (45.91%)
Return on invested capital 0.00% (2.58%) 0.00%

Growth

Metric GENB MNKD Biotechnology median
Revenue growth (TTM) — 31.74% 7.20%
EPS growth (last fiscal year) (13.66%) (80.00%) 29.04%
Revenue growth, 5-year CAGR — 39.89% 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric GENB MNKD Biotechnology median
Debt to equity 0.02 (11.33) 0.00
Current ratio 5.01 2.22 4.83
Net debt to EBITDA 0.97 5.32 1.01

Dividend

Metric GENB MNKD Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GENB MNKD Biotechnology median
Market cap 1.34b 1.35b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack